|
|
|
|
| LEADER |
00000nam a22000005i 4500 |
| 001 |
b3196876 |
| 003 |
MWH |
| 005 |
20191023192307.0 |
| 007 |
cr nn 008mamaa |
| 008 |
121227s1984 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783642823572
|
| 024 |
7 |
|
|a 10.1007/978-3-642-82357-2
|2 doi
|
| 035 |
|
|
|a (DE-He213)978-3-642-82357-2
|
| 050 |
|
4 |
|a E-Book
|
| 072 |
|
7 |
|a MJT
|2 bicssc
|
| 072 |
|
7 |
|a MED033000
|2 bisacsh
|
| 072 |
|
7 |
|a MKC
|2 thema
|
| 245 |
1 |
0 |
|a Adjuvant Chemotherapy of Breast Cancer
|h [electronic resource] :
|b Papers Presented at the 2nd International Conference on Adjuvant Chemotherapy of Breast Cancer, Kantonsspital St. Gallen, Switzerland, March 1 – 3, 1984 /
|c edited by Hans-Jörg Senn.
|
| 250 |
|
|
|a 1st ed. 1984.
|
| 264 |
|
1 |
|a Berlin, Heidelberg :
|b Springer Berlin Heidelberg :
|b Imprint: Springer,
|c 1984.
|
| 300 |
|
|
|a XIV, 246 p.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Recent Results in Cancer Research,
|x 0080-0015 ;
|v 96
|
| 490 |
1 |
|
|a Springer eBook Collection
|
| 505 |
0 |
|
|a Scientific Basis of Adjuvant Chemotherapy in Breast Cancer -- The Preclinical Scientific Basis for Adjuvant Chemotherapy in Breast Cancer -- The Clinical-Scientific Basis of Adjuvant Chemotherapy in Breast Cancer -- Molecular and Cellular Mechanisms Underlying Ineffective Cancer Chemotherapy -- Impact of Early Detection of Breast Cancer on Adjuvant Chemotherapy -- Contribution of Prognostic Factors to Adjuvant Chemotherapy in Breast Cancer -- Review: Scientific Basis of Adjuvant Chemotherapy in Breast Cancer -- Clinical Results I: Experience of Randomized Trials with Surgical Controls -- Scandinavian Trials with a Short Postoperative Course Versus a 12-Cycle Course -- A Brief Overview of Findings from NSABP Trials of Adjuvant Therapy -- CMF Adjuvant Programs at the Milan Cancer Institute -- A Controlled Trial of Adjuvant Chemotherapy with Melphal-an Versus Cyclophosphamide, Methotrexate, and Fluorouracil for Breast Cancer -- Adjuvant Chemoimmunotherapy with LMF + BCG in Node-Negative and Node-Positive Breast Cancer: 8 Year Results -- Ludwig Breast Cancer Trial LBCS III: Chemo-and Endocrine Adjuvant Treatment in Postmenopausal Patients -- Postmenopausal Node-Positive Comparison of Observation with CMFP and CMFP + Tamoxifen Adjuvant Therapy An Eastern Cooperative Oncology Group Trial -- Adjuvant Systemic Therapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group’s Trials of Cyclophosphamide or CMF in Premenopausal and Tamoxifen in Postmenopausal Patients -- Clinical Results II: Experience of Non-Randomized Trials with Historical or Mached Surgical Controls -- FAC + BCG as Adjuvant Therapy in Breast Cancer: An 8-Year Update -- Current Results of the University of Arizona Adjuvant Breast Cancer Trials (1974–1984) -- Significance of Drug Dose, Timing and Radiotherapy in Adjuvant Therapy of Breast Cancer -- The Use of a Natural History Data Base to Compare Outcome Among Several Trials of Adjuvant Chemotherapy for Stage II Breast Cancer -- Clinical Results III: Experience of Randomized Trials Without Surgical Controls -- Adjuvant Systemic Therapy in Postoperative Node-Positive Patients with Breast Carcinoma: The CALGB Trial and the ECOG Premenopausal Trial -- Adjuvant Therapy of Breast Cancer: A Southwest Oncology Group Experience -- Short- or Long-term Chemotherapy for Node-Positive Breast Cancer: LMF 6 Versus 18 Cycles. SAKK Study 27/26 -- Adjuvant Programs for Postmenopausal Women with Node-Positive Breast Cancer: Preliminary Analysis of 5-Year Results -- Review: Experience of Randomized Trials Without Surgical Controls -- Remaining Problems of Adjuvant Chemotherapy in Breast Cancer -- Second Malignant Neoplasms in Operable Carcinoma of the Breast -- Tamoxifen and Combination Chemotherapy as Adjuvant Treatment in Postmenopausal Women with Breast Cancer -- Ludwig Breast Cancer Trials LBCS III and IV: Adjuvant Endocrine Treatment in Postmenopausal Patients -- Problems of Combined Adjuvant Radiochemotherapy -- The Present Dilemma of Adjuvant Chemotherapy: Acceptance and Risks Versus Benefits -- Are Current Worldwide Studies Going to Answer the Important Questions Remaining in Adjuvant Chemotherapy of Breast Cancer? -- Closing Remarks and Outlook -- Closing Remarks and Outlook.
|
| 520 |
|
|
|a H.-J. Senn Adjuvant Chemotherapy (ACT) of breast cancer has now emerged as one of the controversial su):>jects in clinical and also experimental oncology. Driven by growing frustration about stagnating cure rates in breast cancer [1,4] and stimulated by elegant demonstration of highly curative effects of adjuvant systemic therapy in animal models [6, 11] and in several childhood neoplasias [15], researchers introduced ACT to the primary treatment of breast cancer with great hope some 15 years ago. After a first wave of isolated "historic" trials with generally limited but in one case remarkable success [5, 9], a second generation of ACT studies was initiated by NSABP investigators and oncology centers in Europe [2, 6, 13]. These trials were well conducted statistically and diagnostically, and all in the early 1970s included a surgical control arm. Early and intermediate beneficial effects on relapse-free survival (RFS) after 2-3 years median observation time then prompted a whole series of ACT studies in breast cancer. These "third-gener ation" studies usually regarded some positive influence of ACT as a given fact, dropping surgical control regimens and comparing different ACT regimens, hopefully in a prospective, randomized way 1984 Fig. 1. The mushrooming of adjuvant studies in breast cancer XII Introduction [reviews in 3, 14]. The "mushrooming" of ACT studies in breast cancer during the last 10 and especially 5 years is demonstrated in Fig. 1, and it gets really cumbersome even for the insider to keep on top of the multitude of sometimes conflicting data.
|
| 590 |
|
|
|a Loaded electronically.
|
| 590 |
|
|
|a Electronic access restricted to members of the Holy Cross Community.
|
| 650 |
|
0 |
|a Gynecology .
|
| 650 |
|
0 |
|a Oncology .
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Surgery.
|
| 690 |
|
|
|a Electronic resources (E-books)
|
| 700 |
1 |
|
|a Senn, Hans-Jörg.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 830 |
|
0 |
|a Recent Results in Cancer Research,
|x 0080-0015 ;
|v 96
|
| 830 |
|
0 |
|a Springer eBook Collection.
|
| 856 |
4 |
0 |
|u https://holycross.idm.oclc.org/login?auth=cas&url=https://doi.org/10.1007/978-3-642-82357-2
|3 Click to view e-book
|
| 907 |
|
|
|a .b31968764
|b 04-18-22
|c 02-26-20
|
| 998 |
|
|
|a he
|b 02-26-20
|c m
|d @
|e -
|f eng
|g gw
|h 0
|i 1
|
| 912 |
|
|
|a ZDB-2-SME
|
| 912 |
|
|
|a ZDB-2-BAE
|
| 950 |
|
|
|a Medicine (Springer-11650)
|
| 902 |
|
|
|a springer purchased ebooks
|
| 903 |
|
|
|a SEB-COLL
|
| 945 |
|
|
|f - -
|g 1
|h 0
|j - -
|k - -
|l he
|o -
|p $0.00
|q -
|r -
|s b
|t 38
|u 0
|v 0
|w 0
|x 0
|y .i21100391
|z 02-26-20
|
| 999 |
f |
f |
|i 47ea40c2-77e7-5b22-a0d3-fe781907a76e
|s b9f232c2-a89e-563c-bc75-c25bd452f86f
|
| 952 |
f |
f |
|p Online
|a College of the Holy Cross
|b Main Campus
|c E-Resources
|d Online
|e E-Book
|h Library of Congress classification
|i Elec File
|n 1
|